Helus Pharma (HELP) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Helus Pharma (HELP) has outperformed Zevra Therapeutics (ZVRA) over the past year, gaining 9.3% versus a gain of 1.9%. Over five years, ZVRA leads with a +8.8% price change compared with -88.1% for HELP. Zevra Therapeutics is the larger company by market cap ($521.3 million vs $487.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HELP | ZVRA |
|---|---|---|
| Share price | $6.11 | $8.76 |
| Market cap | $487.68M | $521.26M |
| 1-day change | -9.88% | -3.42% |
| YTD return | -25.31% | -2.23% |
| 1-year return | +9.30% | +1.86% |
| 5-year return | -88.09% | +8.82% |
| P/E ratio (TTM) | — | 7.18 |
| Forward P/E | — | 9.84 |
| EPS (TTM) | $-4.25 | $1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $106.47M |
| Revenue growth (YoY) | — | +350.91% |
| Net income (latest FY) | — | $83.23M |
| Gross margin | — | 84.52% |
| Operating margin | — | -59.12% |
| Net margin | — | 78.17% |
| 52-week high | $15.15 | $15.04 |
| 52-week low | $3.76 | $8.01 |
| Distance from 52-week high | -59.67% | -41.74% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +564.81% | +162.56% |
| Average volume | 1.83M | 954.53K |
| Shares outstanding | 79.81M | 59.50M |
| Employees | 100 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Helus Pharma
HELP stock →Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
HELP vs ZVRA FAQ
Which is bigger, Helus Pharma or Zevra Therapeutics?
Zevra Therapeutics (ZVRA) is larger, with a market capitalization of $521.26M compared with $487.68M for Helus Pharma (HELP).
Which stock has performed better over the past year, HELP or ZVRA?
HELP returned +9.30% over the past 12 months, compared with +1.86% for ZVRA (price return, excluding dividends). Past performance does not predict future results.
Are Helus Pharma and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.